Advanced in Platelet Storage Pool Deficiency

Andreas U. Gunther

Giessen, HE, DE 
Advanced in Platelet Storage Pool Deficiency
Giessen, HE, DE 
OverviewLocationsClinical Research

Overview

Andreas Gunther practices in Giessen, Germany. Mr. Gunther is rated as an Advanced expert by MediFind in the treatment of Platelet Storage Pool Deficiency. His top areas of expertise are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Lung Transplant.

His clinical research consists of co-authoring 199 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Platelet Storage Pool Deficiency.

Gender
Male

Locations

Giessen, HE, Germany
Other Locations
Munich, BY, Germany
Tuebingen, BW, Germany
Greifenstein, HE 35753, Germany
Waldhof, MV, Germany
Heidelberg, BW 69120, Germany
Germany
Aachen, NW, Germany
Hessen, ST, Germany
Marburg An Der Lahn, HE, Germany
Augsburg, BY 86135, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank)
The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Other
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
Enrollment Status: Completed
Publish Date: October 27, 2021
Intervention Type: Other
Study Phase: Not Applicable
Inhaled Steroids and Control of Severe Asthma: Comparison of the AKITA Technology Versus Conventional MDI (INHALE)
Inhaled Steroids and Control of Severe Asthma: Comparison of the AKITA Technology Versus Conventional MDI (INHALE)
Enrollment Status: Terminated
Publish Date: November 10, 2020
View 5 Less Clinical Trials

199 Total Publications

Dyspnoea Units: Recommendations on personnel, structural and technical requirements
Dyspnoea Units: Recommendations on personnel, structural and technical requirements
Journal: Pneumologie (Stuttgart, Germany)
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gunther's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile